SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
March 12, 2024 08:14 ET
|
SciSparc Ltd
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March 12, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC)...
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
March 08, 2024 07:11 ET
|
SciSparc Ltd
TEL AVIV, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
March 07, 2024 07:49 ET
|
SciSparc Ltd
The Company's most recent patent further solidifies its position, complementing existing grants in the U.S., Japan, Australia and other key jurisdictions TEL AVIV, Israel, March 07, 2024 ...
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
March 06, 2024 16:41 ET
|
SciSparc Ltd
TEL AVIV, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
February 29, 2024 08:35 ET
|
SciSparc Ltd
The SCI- 210 treatment is now available at clinical site for autism spectrum disorder clinical trial in pediatric patients, in accordance with enrollment initiation TEL AVIV, Israel, Feb. 29,...
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
February 27, 2024 07:58 ET
|
SciSparc Ltd
TEL AVIV, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
February 20, 2024 07:14 ET
|
SciSparc Ltd
TEL AVIV, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
January 29, 2024 07:18 ET
|
SciSparc Ltd
The clinical trial for SCI-210 will be conducted in Israel, after which the company aims to move forward with the commercialization process of SCI-210 first in the Israeli market TEL AVIV,...
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
January 24, 2024 07:42 ET
|
SciSparc Ltd
TEL AVIV, Israel, Jan. 24, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of...
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
January 19, 2024 09:28 ET
|
SciSparc Ltd
TEL AVIV, Israel, Jan. 19, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...